DTIL - Precision BioSciences

-

$undefined

N/A

(N/A)

Precision BioSciences NASDAQ:DTIL Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its wholly proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple 'off-the-shelf' CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist.

Location: 302 E Pettigrew St Ste A100, North Carolina, 27701-2393, United States | Website: precisionbiosciences.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-33.74M

Cash

123.6M

Avg Qtr Burn

-16.34M

Short % of Float

3.67%

Insider Ownership

6.78%

Institutional Own.

45.15%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ECUR-506 Details
Ornithine transcarbmylase deficiency

Phase 1/2

Data readout

Azer-cel (PBCAR0191) (azercabtagene zapreleucel) Details
Cancer, B-cell lymphoma, Diffuse large B cell lymphoma

Phase 1/2

Update

PBCAR19B (CD19 Allogeneic CAR-T) Details
Non-Hodgkin lymphoma, Cancer, Diffuse large B cell lymphoma

Phase 1

Update

PBGENE - HBV Details
Chronic hepatitis B, Viral infection, Liver disease

Phase 1

Initiation

PBCAR20A (targeting CD20) Details
Non-Hodgkin lymphoma, Cancer, Chronic lymphocytic leukemia

Failed

Discontinued

PBCAR269A (BCMA) Details
Cancer, Multiple myeloma

Failed

Discontinued